MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$3,716,323
Unit: Dollar
Positive Cash Flow Breakdown
Stock-based compensation
Negative Cash Flow Breakdown
Net loss
Accounts payable and accrued exp...
Prepaid expenses and deposits
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-1,826,229
-3,179,278
-1,703,210
-1,998,662
Stock-based compensation
195,735
178,422
111,131
33,279
Prepaid expenses and deposits
625,623
-240,697
-467,974
-151,865
Other receivables
242,177
7,900
-295,753
-681,550
Related party payable
-196,434
1,001,229
-328,315
-328,316
Accounts payable and accrued expenses
-889,768
614,301
-365,263
-603,224
Deferred revenue
-
-
-378,176
0
Deferred grant income
-131,827
-251,663
-
-
Net cash used in operating activities
-3,716,323
-1,404,192
-1,900,106
-2,735,876
Proceeds from issuance of common stock, net
-
-
0
9,863,883
Proceeds from exercise of warrants and stock options
-
-
0
0
Net cash provided by financing activities
-
-
0
9,863,883
Net decrease in cash, cash equivalents, and restricted cash
-3,716,323
-1,404,192
-1,900,106
7,128,007
Cash, cash equivalents, and restricted cash at beginning of the period
15,638,655
17,042,847
18,942,953
19,192,440
Cash, cash equivalents, and restricted cash at end of the period
11,922,332
15,638,655
17,042,847
18,942,953
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net decrease in
cash, cash...
-$3,716,323
(49.63%↑ Y/Y)
Stock-based compensation
$195,735
(-50.21%↓ Y/Y)
Net cash used in
operating activities
-$3,716,323
(49.63%↑ Y/Y)
Canceled cashflow
$195,735
Net loss
-$1,826,229
(78.42%↑ Y/Y)
Accounts payable and
accrued expenses
-$889,768
(-273.13%↓ Y/Y)
Prepaid expenses and
deposits
$625,623
(-21.29%↓ Y/Y)
Other receivables
$242,177
(136.02%↑ Y/Y)
Related party payable
-$196,434
(81.36%↑ Y/Y)
Deferred grant income
-$131,827
Buy us a coffee
Marker Therapeutics, Inc. (MRKR)
Marker Therapeutics, Inc. (MRKR)